These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23898602)

  • 21. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 22. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR; DeYoung MB
    Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
    Alves C; Batel-Marques F; Macedo AF
    Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.
    Crasto W; Khunti K; Davies MJ
    Drugs Today (Barc); 2011 Nov; 47(11):839-56. PubMed ID: 22146227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Not Available].
    Salvador J; Gaztambide S
    Med Clin (Barc); 2014; 143 Suppl 2():1. PubMed ID: 25326835
    [No Abstract]   [Full Text] [Related]  

  • 28. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 29. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
    Ross SA; Ballantine J
    Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of type 2 diabetes mellitus with GLP-1 agonists].
    Haluzík M; Urbanová M; Trachta P
    Vnitr Lek; 2011 Apr; 57(4):411-5. PubMed ID: 21612070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
    Drucker DJ; Nauck MA
    Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F; Wu S; Guo S; Yu K; Yang Z; Li L; Zhang Y; Quan X; Ji L; Zhan S
    Diabetes Res Clin Pract; 2015 Oct; 110(1):26-37. PubMed ID: 26358202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exenatide: excessive weight loss.
    Prescrire Int; 2011 Jan; 20(112):17. PubMed ID: 21462789
    [No Abstract]   [Full Text] [Related]  

  • 39. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
    Zhang L; Wang L; Meng Z; Gan H; Gu R; Wu Z; Gao L; Zhu X; Sun W; Li J; Zheng Y; Dou G
    Biochem Biophys Res Commun; 2014 Mar; 445(2):511-6. PubMed ID: 24565847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists].
    Consoli A; Di Biagio R
    G Ital Cardiol (Rome); 2012 Dec; 13(12 Suppl 1):17S-22S. PubMed ID: 23258125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.